MARKET

GSK

GSK

Glaxosmithkline
NYSE

Real-time Quotes | Nasdaq Last Sale

43.56
+0.28
+0.65%
After Hours: 43.40 -0.16 -0.37% 16:42 05/19 EDT
OPEN
43.08
PREV CLOSE
43.28
HIGH
43.76
LOW
43.06
VOLUME
7.85M
TURNOVER
0
52 WEEK HIGH
46.97
52 WEEK LOW
36.41
MARKET CAP
110.73B
P/E (TTM)
16.42
1D
5D
1M
3M
1Y
5Y
4 Large Drug Stocks to Watch as the Industry Recovers
Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.
Zacks · 7h ago
GSK goes ex-dividend tomorrow
GSK (NYSE:GSK) had declared GBP 0.14/share quarterly dividend, -39.1% decrease from prior dividend of GBP 0.23. Payable July 1; for shareholders of record May 20; ex-div May 19. See GSK
Seekingalpha · 1d ago
AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies
AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.
Zacks · 1d ago
Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.
Zacks · 2d ago
Ideaya Biosciences price target raised to new Street high at Roth; sees 341% upside
Roth Capital Partners is raising its price target on Ideaya Biosciences (NASDAQ:IDYA) to a Street high of $46 from $42 (341% upside based on Monday's close) while maintaining a buy
Seekingalpha · 2d ago
After 2 decades GlaxoSmithKline changes name to GSK ahead of consumer spinoff
After more than 20 years, when SmithKline Beecham and GlaxoWellcome merged to form GlaxoSmithKline (NYSE:GSK), the British healthcare company changed its name to GSK plc. The pharma giant is currently on track to
Seekingalpha · 2d ago
Unilever edges lower as SocGen shifts to ‘Sell’ in double downgrade
Unilever (NYSE:UL) is no longer loved by Societe Generale as the bank sees slowing sales and squeezed margins ahead. Shares of the Anglo-Dutch consumer goods company fell 1.13% in mid-day
Seekingalpha · 3d ago
BRIEF-Glaxosmithkline Confirms It Has Changed Its Name To GSK PLC
reuters.com · 3d ago
More
No Data
Learn about the latest financial forecast of GSK. Analyze the recent business situations of Glaxosmithkline through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
0.00%Buy
60.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average GSK stock price target is 49.81 with a high estimate of 52.50 and a low estimate of 45.94.
High52.50
Average49.81
Low45.94
Current 43.56
EPS
Actual
Estimate
0.250.510.761.01
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 1.24K
Institutional Holdings: 356.09M
% Owned: 14.01%
Shares Outstanding: 2.54B
TypeInstitutionsShares
Increased
312
19.49M
New
179
6.05M
Decreased
246
21.58M
Sold Out
49
442.61K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.15%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Non-Executive Chairman/Independent Director
Jonathan Symonds
Chief Executive Officer/Executive Director
Emma Walmsley
Chief Financial Officer/Executive Director
Iain Mackay
Corporate Executive
Roger Connor
Corporate Executive
Brian McNamara
Corporate Executive
Regis Simard
Corporate Executive
Phil Thomson
Corporate Executive
Deborah Waterhouse
Chief Human Resource Officer
Diana Conrad
Senior Vice President/Chief Compliance Officer/General Counsel
James Ford
Senior Vice President
Sally Jackson
Chief Technology Officer
Shobie Ramakrishnan
Chief Scientific Officer/Executive Director
Hal Barron
Other
Luke Miels
Other
David Redfern
Other
Tony Wood
Secretary
Victoria Whyte
Non-Executive Independent Director
Charles Bancroft
Non-Executive Independent Director
Marvinder Banga
Non-Executive Independent Director
Anne Beal
Non-Executive Independent Director
Vivienne Cox
Non-Executive Independent Director
Harry Dietz
Non-Executive Independent Director
Lynn Elsenhans
Non-Executive Independent Director
Laurie Glimcher
Non-Executive Independent Director
Jesse Goodman
Non-Executive Independent Director
Urs Rohner
No Data
No Data
About GSK
GlaxoSmithKline PLC is a global healthcare company. The Company researches and develops a range of products in three primary areas: Pharmaceuticals, Vaccines and Consumer Healthcare. Its product formulations include tablets, creams/ointments, inhalers, injections, liquids and sterile products. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency virus (HIV), immuno-inflammation and oncology. Its Vaccines business has a portfolio of vaccines to help protect people from a range of diseases throughout their lives. Its vaccines tackle diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza. Its Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands that consumers trust, and experts recommend for oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements.

Webull offers kinds of GlaxoSmithKline plc (ADR) stock information, including NYSE:GSK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GSK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GSK stock methods without spending real money on the virtual paper trading platform.